Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Leases (2019 - 2025)

Historic Current Leases for Syndax Pharmaceuticals (SNDX) over the last 7 years, with Q3 2025 value amounting to $329000.0.

  • Syndax Pharmaceuticals' Current Leases fell 6092.64% to $329000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $329000.0, marking a year-over-year decrease of 6092.64%. This contributed to the annual value of $471000.0 for FY2024, which is 5449.28% down from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Current Leases stood at $329000.0 for Q3 2025, which was down 6092.64% from $344000.0 recorded in Q2 2025.
  • In the past 5 years, Syndax Pharmaceuticals' Current Leases registered a high of $1.0 million during Q1 2024, and its lowest value of $299000.0 during Q2 2022.
  • Its 5-year average for Current Leases is $577105.3, with a median of $454000.0 in 2023.
  • Its Current Leases has fluctuated over the past 5 years, first soared by 22006.69% in 2023, then plummeted by 6493.37% in 2025.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Current Leases stood at $361000.0 in 2021, then increased by 20.22% to $434000.0 in 2022, then skyrocketed by 138.48% to $1.0 million in 2023, then crashed by 54.49% to $471000.0 in 2024, then plummeted by 30.15% to $329000.0 in 2025.
  • Its Current Leases was $329000.0 in Q3 2025, compared to $344000.0 in Q2 2025 and $377000.0 in Q1 2025.